• About Us
    • Fact Checking Policy
    • Ownership & funding information
    • Volunteer
  • Subscribe
  • Letter submission
    • Submissions Policy
  • Contact Us
The Online Citizen Asia
  • Opinion
    • Editorial
    • Commentaries
    • Letters
    • Comments
  • Current Affairs
    • Singapore
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Arts & Culture
    • Consumer Watch
    • NGO
    • Lifestyle
    • Travel
  • Politics
    • Civil Society
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
No Result
View All Result
  • Opinion
    • Editorial
    • Commentaries
    • Letters
    • Comments
  • Current Affairs
    • Singapore
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Arts & Culture
    • Consumer Watch
    • NGO
    • Lifestyle
    • Travel
  • Politics
    • Civil Society
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
No Result
View All Result
The Online Citizen Asia
No Result
View All Result

Japan approves remdesivir for coronavirus treatment

by The Online Citizen
08/05/2020
in Health, International
Reading Time: 2 mins read
1

Japan on Thursday authorised the antiviral drug remdesivir to treat coronavirus patients, the government said, with an eye to approving another medication Avigan this month.
This makes Japan the second country to approve the drug after US regulators authorised it on Friday for emergency use against severe cases of COVID-19.
“Remdesivir was approved under exceptional measures,” a health, labour and welfare ministry official said.
“It was our country’s first such approval for the treatment of coronavirus patients,” the official told AFP.
Prime Minister Shinzo Abe said last week the government was getting ready to give a speedy green light to the experimental drug developed by US firm Gilead Sciences.
The US go-ahead came after a major clinical trial showed remdesivir — originally developed to treat Ebola — shortened the time to recovery in some patients by a third.
The difference in mortality rate was not statistically significant.
Remdesivir, which is administered by injection, was already available to some patients who enrolled in clinical trials around the world.
“The Japanese approval of remdesivir is in recognition of the urgent need to treat critically ill patients in Japan. It is a reflection of the exceptional circumstances of this pandemic,” said Merdad Parsey, chief medical officer at Gilead Sciences.
Remdesivir incorporates itself into the virus’s genome, short-circuiting its replication process.
The Gilead statement noted that clinical trials are ongoing to evaluate the safety and efficacy of remdesivir for the treatment of COVID-19.
As for Avigan, developed by Japanese firm Fujifilm Toyama Chemical, top government spokesman Yoshihide Suga said the government “aims to approve it this month” if a clinical trial involving 100 patients proves effective.
The drug, whose generic name is favipiravir, was approved for use in Japan in 2014 but only in flu outbreaks that are not being effectively addressed by existing medications.
It is not available on the market and can only be manufactured and distributed at the request of the Japanese government.
Favipiravir, which can be taken orally as a pill, works by blocking the ability of a virus to replicate inside a cell.
Avigan has been shown in animal studies to affect foetal development, meaning it is not given to pregnant women.
– AFP

For just US$7.50 a month, sign up as a subscriber on The Online Citizen Asia (and enjoy ads-free experience on our site) to support our mission to transform TOC into an alternative mainstream press.
Tags: AFP

Related Posts

WHO panel in talks on COVID emergency status
AFP

WHO panel in talks on COVID emergency status

27/01/2023
Chinese property giant Evergrande under ‘tremendous pressure’
China

Chinese property giant Evergrande under ‘tremendous pressure’

14/09/2021
Australia’s capital Canberra to enter virus lockdown
Health

Virus lockdown extended for Australia’s capital

14/09/2021
Messenger RNA COVID vaccines 66% effective against Delta: US study
Health

UK to vaccinate over 12s against COVID

14/09/2021
Politics

Facebook shields VIPs from some of its rules: report

14/09/2021
Malaysian PM, opposition in deal to boost stability
Malaysia

Malaysian PM, opposition in deal to boost stability

14/09/2021
Subscribe
Connect withD
Login
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
Notify of
Connect withD
I allow to create an account
When you login first time using a Social Login button, we collect your account public profile information shared by Social Login provider, based on your privacy settings. We also get your email address to automatically create an account for you in our website. Once your account is created, you'll be logged-in to this account.
DisagreeAgree
1 Comment
Newest
Oldest Most Voted
Inline Feedbacks
View all comments

Latest posts

Sixteen killed in China highway pile-up

Sixteen killed in China highway pile-up

05/02/2023

Are IT jobs in Singapore flooded by foreigners?

05/02/2023
Nine missing after fishing boat capsizes in South Korea

Nine missing after fishing boat capsizes in South Korea

05/02/2023
Piercings and prayer: Malaysian Hindus celebrate Thaipusam

Piercings and prayer: Malaysian Hindus celebrate Thaipusam

05/02/2023
Grab SG appoints PAP MP Tin Peiling as director of public affairs and policy

Netizens question Tin Pei Ling’s conflict of interest as Grab’s director of Public Affairs and Member of Parliament

05/02/2023
Why is Gautam Adani’s Indian empire in turmoil?

Indian regulator reassures investors after Adani rout

05/02/2023
Cognizant India transfers staff to work in Singapore as recently as this year

Local IT grads can’t find jobs while engineers constantly transferred from India to work in SG under CECA

05/02/2023
Family of student killed in accident involving retired police officer, calls for transparency from Indonesian police

Family of student killed in accident involving retired police officer, calls for transparency from Indonesian police

04/02/2023

Trending posts

Former Singaporean shares change of life in Australia with annual pay of S$80,000 as a plumber

Former Singaporean shares change of life in Australia with annual pay of S$80,000 as a plumber

by Yee Loon
30/01/2023
25

...

They have done a fine job of confusing us about the jobs situation

They have done a fine job of confusing us about the jobs situation

by Augustine Low
01/02/2023
47

...

Adani’s brother runs SG company and registers as director with local ID

Adani’s brother runs SG company and registers as director with local ID

by Correspondent
03/02/2023
26

...

Cognizant India transfers staff to work in Singapore as recently as this year

Local IT grads can’t find jobs while engineers constantly transferred from India to work in SG under CECA

by Correspondent
05/02/2023
33

...

Excessively charging for an essential need, and calling it affordable because people still can pay for it?

by Terry Xu
31/01/2023
40

...

Singapore Law Watch removes commentary on CPIB’s decision to not prosecute former Keppel executives

Singapore Law Watch removes commentary on CPIB’s decision to not prosecute former Keppel executives

by The Online Citizen
02/02/2023
19

...

May 2020
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
« Apr   Jun »

The Online Citizen is a regional online publication based in Taiwan and formerly Singapore’s longest-running independent online media platform.

Navigation

  • Editorial
  • Commentaries
  • Opinion
  • Politics
  • Community

Support

  • Contact Us
  • Letter submission
  • Membership subscription

Follow Us

  • Facebook
  • Twitter
  • YouTube
  • Instagram
  • Fact Checking Policy
  • Privacy Policy

© 2022 - 2023 The Online Citizen Asia

No Result
View All Result
  • Opinion
    • Editorial
    • Commentaries
    • Comments
  • Current Affairs
    • Malaysia
    • Indonesia
    • China
    • ASEAN
    • Asia
    • International
  • Finance
    • Economics
    • Labour
    • Property
    • Business
  • Community
    • Civil Society
    • Arts & Culture
    • Consumer Watch
    • NGO
  • Politics
    • Parliament
    • Transport
    • Education
    • Environment
    • Health
    • Housing
  • Law & Order
    • Legislation
    • Court Cases
  • Lifestyle
    • Travel
  • Subscribers login

© 2022 - 2023 The Online Citizen Asia

wpDiscuz